Synonym
PF-6808472; PF 6808472; PF6808472; OX44; OX-44; OX 44;
IUPAC/Chemical Name
4-{4-[4-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-6-prop-2-ynylcarbamoyl-pyrimidin-2-yl]-piperazin-1-ylmethyl}-benzenesulfonyl fluoride
InChi Key
ZBSPMOBILDLOCV-UHFFFAOYSA-N
InChi Code
InChI=1S/C25H27FN8O3S/c1-2-9-27-24(35)21-15-22(29-23-14-20(31-32-23)18-5-6-18)30-25(28-21)34-12-10-33(11-13-34)16-17-3-7-19(8-4-17)38(26,36)37/h1,3-4,7-8,14-15,18H,5-6,9-13,16H2,(H,27,35)(H2,28,29,30,31,32)
SMILES Code
O=S(C1=CC=C(CN2CCN(C3=NC(C(NCC#C)=O)=CC(NC4=NNC(C5CC5)=C4)=N3)CC2)C=C1)(F)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
PF-6808472 is a cell permeable covalent probe suitable for click chemistry designated to measure kinase selectivity in intact cells.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
538.60
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Freeman-Cook, K. D., Hoffman, R. L., Behenna, D. C., Boras, B., Carelli, J., Diehl, W., ... & Dann, S. (2021). Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer. Journal of medicinal chemistry, 64(13), 9056-9077.
Leung, C. O. N., Yang, Y., Leung, R. W. H., So, K. K. H., Guo, H. J., Lei, M. M. L., ... & Lee, T. K. W. (2023). Broad-spectrum kinome profiling identifies CDK6 upregulation as a driver of lenvatinib resistance in hepatocellular carcinoma. Nature Communications, 14(1), 6699.
